Acetylation-dependent regulation of BRAF oncogenic function

Cell Rep. 2022 Jan 18;38(3):110250. doi: 10.1016/j.celrep.2021.110250.

Abstract

Aberrant BRAF activation, including the BRAFV600E mutation, is frequently observed in human cancers. However, it remains largely elusive whether other types of post-translational modification(s) in addition to phosphorylation and ubiquitination-dependent regulation also modulate BRAF kinase activity. Here, we report that the acetyltransferase p300 activates the BRAF kinase by promoting BRAF K601 acetylation, a process that is antagonized by the deacetylase SIRT1. Notably, K601 acetylation facilitates BRAF dimerization with RAF proteins and KSR1. Furthermore, K601 acetylation promotes melanoma cell proliferation and contributes to BRAFV600E inhibitor resistance in BRAFV600E harboring melanoma cells. As such, melanoma patient-derived K601E oncogenic mutation mimics K601 acetylation to augment BRAF kinase activity. Our findings, therefore, uncover a layer of BRAF regulation and suggest p300 hyperactivation or SIRT1 deficiency as potential biomarkers to determine ERK activation in melanomas.

Keywords: BRAF; SIRT1; acetylation; melanoma; p300.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylation
  • Animals
  • Enzyme Activation / physiology
  • Female
  • Heterografts
  • Humans
  • Melanoma, Experimental / enzymology*
  • Melanoma, Experimental / genetics*
  • Mice
  • Mice, Nude
  • Mutation
  • Protein Processing, Post-Translational
  • Proto-Oncogene Proteins B-raf / genetics
  • Proto-Oncogene Proteins B-raf / metabolism*
  • p300-CBP Transcription Factors

Substances

  • p300-CBP Transcription Factors
  • p300-CBP-associated factor
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf